Sanofi Genzyme, a global business unit of Sanofi, has secured a $37.6m contract from the Biomedical Advanced Research and Development Authority (BARDA), for the supply and manage inventory for Leukine.
Leukine is a treatment for acute radiation syndrome, an illness that can damage organs including the bone marrow, gastrointestinal tract and lungs.
It can also cause neutropenia, an abnormally low level of white blood cells that fight infection called neutrophils.
Sanofi Genzyme Rare Diseases global head Richard Peters said: “According to the centres for disease control and prevention, the cause of death in most cases of acute radiation syndrome is the destruction of the person's bone marrow.
“We are pleased to be able to partner with BARDA to support public health.”
In 2013, Sanofi secured a $36.5m contract for late stage development and procurement of Leukine.
The company has conducted tests regarding the potential use of Leukine in patients acutely exposed to myelosuppressive doses of radiation.
Sanofi Genzyme is planning to submit a supplemental biologics licence application (sBLA) to the US Food and Drug Administration in 2017.
BARDA develops vaccines, drugs, therapies, and diagnostic tools for public-health medical emergencies.